Methods of identifying modulators of the estrogen receptor

• US 6,204,067 B1
• Filed: 06/17/1999
• Issued: 03/20/2001
• Est. Priority Date: 06/17/1999
• Status: Expired due to Fees

• Current Assignee: The Board of Trustees of Michigan State University (Michigan State University), Rockefeller University
• Original Assignee: The Board of Trustees of Michigan State University (Michigan State University)
• Inventors: Chen, Yu, Simon, Sanford M., Schindler, Melvin S.
• Primary Examiner(s): Marschel, Ardin H.
• Assistant Examiner(s): Moran, Marjorie A.
• Application Number:
  US09/335,457
• Time in Patent Office: 642 Days
• Field of Search: 564/324, 436/163, 436/172, 436/63, 436/111, 435/7.8
• US Class Current: 436/163
• CPC Class Codes: G01N 2021/6439 with indicators, stains, dyes, tags, labels, marks
• CPC Class Codes: G01N 21/6428 Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" in vivo A61B5/00; immunoassay G01N33/53
• CPC Class Codes: G01N 21/80 Indicating pH value
• CPC Class Codes: G01N 2333/723 Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/743 Steroid hormones
• CPC Class Codes: Y10T 436/173845 Amine and quaternary ammonium

Abstract

The present invention discloses the mechanism of tamoxifen mediated inhibition of acidification. This mechanism information is then used to design methods of identifying compounds that will have the pharmaceutical effect of tamoxifen without the corresponding side-effects.

Claims

1. A method of selecting for an agent which binds to the estrogen receptor but which dissipates a transmembrane pH gradient to a lesser extent than does tamoxifen, wherein the method comprises:

(a) choosing an agent which binds to the estrogen receptor,

(b) choosing a vesicle and conditions wherein the pH inside the vesicle differs from the pH outside the vesicle, whereby a transmembrane pH gradient is formed,

(c) employing conditions under which tamoxifen dissipates the transmembrane pH gradient in the vesicle of step (b), and, in the absence of tamoxifen, contacting the agent of step (a) with the vesicle of step (b),

(d) measuring any change in the magnitude of the transmembrane pH gradient of the vesicle when contacted with the agent, and comparing the change measured to that seen when the vesicle is separately contacted with tamoxifen,

(e) selecting for the agent when the comparison of step (d) indicates that the agent dissipates the transmembrane pH gradient to a lesser extent than does tamoxifen.

2. The method of claim 1 wherein the agent does not measurably dissipate the transmembrane pH gradient.

3. The method of claim 1 wherein the change in the magnitude of the transmembrane pH gradient is measured with a fluorescent probe.

4. The method of claim 3 wherein the fluorescent probe is acridine orange.

5. The method of claim 1 wherein the vesicle is selected from the group consisting of a cell, a mammalian organelle, a yeast vacuole, an inverted bacterial membrane vesicle, and a liposome.

6. The method of claim 5 wherein the vesicle is a mammalian organelle.

7. The method of claim 6 wherein the mammalian organelle is a recycling endosome and wherein the change in the magnitude of the transmembrane pH gradient is measured with a fluorescent-labeled transferrin.

8. The method of claim 5 wherein the vesicle is a liposome.

9. The method of claim 8 wherein the change in the magnitude of the transmembrane pH gradient is measured with pyranine.

10. The method of claim 1, further comprising:

(f) measuring a surface membrane charge of the vesicle before contact with either the agent or tamoxifen,

(g) measuring a surface membrane charge of the vesicle after contact with either tamoxifen or the agent, and comparing the results,

(h) selecting for the agent if the agent meets the conditions of step (e) and if the agent alters the surface membrane charge of the vesicle to a lesser extent than does tamoxifen.

11. A method of selecting for an agent which binds the estrogen receptor but which alters a surface membrane charge to a lesser extent than does tamoxifen, comprising:

(a) choosing an agent which binds to the estrogen receptor,

(b) selecting a vesicle and conditions under which tamoxifen is known to alter a surface membrane charge of the vesicle,

(c) in the absence of tamoxifen, contacting the agent of step (a) with the vesicle under the conditions of step (b),

(d) measuring any alteration in the surface membrane charge of the vesicle upon contact with the agent, and comparing the measured alteration to that seen when the vesicle is separately contacted with tamoxifen,

(e) selecting an agent when the alteration in the surface membrane charge in the presence of the agent is less than the alteration in the presence of tamoxifen.

12. The method of claim 11 wherein the agent does not measurably alter the surface membrane charge.

13. The method of claim 11 wherein the vesicle is selected from the group consisting of a cell, a mammalian organelle, a yeast vacuole, an inverted bacterial membrane vesicle, and a liposome.

14. A method of selecting for an agent which is an antagonist of the estrogen receptor but which dissipates a transmembrane pH gradient to a lesser extent than does tamoxifen, wherein the method comprises:

(a) choosing an agent which is an antagonist of the estrogen receptor,

(b) choosing a vesicle and conditions wherein the pH inside the vesicle differs from the pH outside the vesicle, whereby a transmembrane pH gradient is formed,

(c) employing conditions under which tamoxifen dissipates the transmembrane pH gradient in the vesicle of step (b), and in the absence of tamoxifen, contacting the agent of step (a) with the vesicle of step (b),

(d) measuring any change in the magnitude of the transmembrane pH gradient of the vesicle when contacted with the agent, and comparing the change measured to that seen when the vesicle is separately contacted with tamoxifen,

(e) selecting for the agent when the comparison of step (d) indicates that the agent dissipates the transmembrane pH gradient to a lesser extent than does tamoxifen.

15. The method of claim 14 wherein the agent does not measurably dissipate the transmembrane pH gradient.

16. The method of claim 14 wherein the change in the magnitude of the transmembrane pH gradient is measured with a fluorescent probe.

17. The method of claim 16 wherein the fluorescent probe is acridine orange.

18. The method of claim 14 wherein the vesicle is selected from the group consisting of a cell, a mammalian organelle, a yeast vacuole, an inverted bacterial membrane vesicle, and a liposome.

19. The method of claim 18 wherein the vesicle is a mammalian organelle.

20. The method of claim 19 wherein the mammalian organelle is a recycling endosome and wherein the change in the magnitude of the transmembrane pH gradient is measured with a fluorescent-labeled transferrin.

21. The method of claim 18 wherein the vesicle is a liposome.

22. The method of claim 21 wherein the change in the magnitude of the transmembrane pH gradient is measured with pyranine.

23. The method of claim 14, further comprising:

(f) measuring a surface membrane charge of the vesicle before contact with either the agent or tamoxifen,

(g) measuring a surface membrane charge of the vesicle after contact with either tamoxifen or the agent, and comparing the results,

(h) selecting for the agent if the agent meets the conditions of step (e) and if the agent alters the surface membrane charge of the vesicle to a lesser extent than does tamoxifen.

24. A method of selecting for an agent is an antagonist of the estrogen receptor but which alters a surface membrane charge to a lesser extent than does tamoxifen, comprising:

(a) choosing an agent which is an antagonist of the estrogen receptor,

(b) selecting a vesicle and conditions under which tamoxifen is known to alter a surface membrane charge of the vesicle,

(c) in the absence of tamoxifen, contacting the agent of step (a) with the vesicle under the conditions of step (b),

(d) measuring any alteration in the surface membrane charge of the vesicle upon contact with the agent, and comparing the measured alteration to that seen when the vesicle is separately contacted with tamoxifen,

(e) selecting an agent when the alteration in the surface membrane charge in the presence of the agent is less than the alteration in the presence of tamoxifen.

25. The method of claim 24 wherein the agent does not measurably alter the surface membrane charge.

26. The method of claim 24 wherein the vesicle is selected from the group consisting of a cell, a mammalian organelle, a yeast vacuole, an inverted bacterial membrane vesicle, and a liposome.